Recent warnings from experts highlight potential risks associated with popular weight-loss medications like Ozempic and Wegovy. While these drugs can lead to significant weight loss—up to 20%—research indicates they may also negatively impact bone health, leading to an increased risk of fractures and osteoporosis.
Research Findings
Studies presented at the American Society for Bone and Mineral Research have raised alarms regarding the long-term effects of these weight-loss drugs. One notable study, published in the medical journal JAMA, examined 200 participants using these medications. The findings revealed that individuals taking the drugs experienced a reduction in hip and spine bone mineral density compared to those receiving a placebo or following an exercise regimen.
Dr. Taher Mahmud, founder of the London Osteoporosis Clinic, emphasizes the importance of this information: “The weight-loss benefits are undeniable, but the evidence also shows loss of lean mass and bone density, which is concerning, particularly for patients with conditions like osteoporosis, who are vulnerable to fractures.”
Understanding the Medications
Ozempic and Wegovy contain semaglutide, a GLP-1 agonist that helps to suppress hunger. While these medications have demonstrated benefits in reducing the risk of death from various causes—up to 23% lower overall mortality in obese and overweight patients over three years—they also present risks, especially for those predisposed to bone health issues.
Research from Harvard Medical School has shown that patients on semaglutide experienced a 29% lower chance of dying from heart attacks and strokes within just two months of treatment. However, Dr. Mahmud cautions that this data raises concerns for individuals already at heightened risk for osteoporosis or fractures, such as those with obesity or type 2 diabetes.
Government Action and Recommendations
In response to the growing interest in these medications, the government recently announced plans to offer them to unemployed individuals. However, experts warn that widespread distribution of these injections could inadvertently lead to an increase in osteoporosis cases, resulting in dangerous bone fractures and falls.
Dr. Mahmud stresses the importance of incorporating exercise into treatment plans for patients on GLP-1 drugs. “The importance of strength training, as well as cardiovascular exercise, should be promoted to help protect against muscle and bone loss,” he advises.
Conclusion
While addressing obesity is crucial, it is essential to combine medical interventions with education and support. Patients using GLP-1 agonists must be informed about the importance of good nutrition and weight-bearing exercise to mitigate potential risks to bone health.
Related Topic:
